in rantes driven COVID, it is very different. W

Quote:

---

in rantes driven COVID, it is very different.

---

What would make a difference is the level of expression of CCR5. In that case the drug with the higher level of occupancy would have greater effect.

Quote:

---

If anything even in HIV Mav could be superior in binding only a head to head study would resolve that hypothesis.

---

With the same MOA what would be indicative of CCR5 occupancy would be the efficacy. Leronlimab has clearly superior efficacy.